Introducing Insightful Moments™, a Rare Disease Patient Education Series
-
Introducing Insightful Moments™, a Rare Disease Patient Education Series
En español haz clic aquí Living with a rare disease or caring for someone with a rare disease comes with many challenges. In addition to processing new and complicated information and making countless decisions, it can be tough to know where to turn to for help, or where to even begin. To help support patients…
-
Webinar: Rare Paediatric Neurological Diseases: A Focus on Europe
Wednesday, 23 March 2022 – 14:00 – 15:00 (CET) PTC Therapeutics invites you to participate in a multi-stakeholder webinar to present the findings of the Economist Impact* report ‘Rare paediatric neurological diseases: A focus on Europe’ and discuss how policymakers, industry, healthcare providers and patients can collaborate to improve care and outcomes. Rare paediatric neurological…
-
“A Transformative Experience”: Talent Pipeline Program Alumni Share their Experiences
In 2020, PTC launched its Talent Pipeline Program (TPP) with the goal of creating opportunities for new graduates during a time when many talented and hardworking students were rightfully worried about being able to enter the workforce. As we open our application period for our second “class” today, we checked in with a few TPP…
-
#DuchenneCan live every day like the best day ever
Laura McLinn is a mother, caregiver and advocate from Indianapolis, IN, USA. When her son was diagnosed with Duchenne at 3-years-old their lives shattered; they had never heard of Duchenne and suddenly could no longer see their son’s future. However, the McLinn family no longer mourns the life that Jordan could’ve had but now embrace…
-
What’s in Store for PTC in 2022
Last week, we presented at the 40th Annual J.P. Morgan Healthcare Conference, an annual healthcare investment symposium connecting healthcare industry leaders, innovators, and the broader healthcare industry. Even though this year’s meeting was (once again) virtual, the excitement for everything that’s to come in 2022 was palpable – especially for us at PTC, as 2022…
-
Make an Impact as PTC’s New Talent Management Specialist
At PTC Therapeutics, our deeply committed #onePTC team helps us achieve our mission to help extend life’s moments for patients with rare diseases and their loved ones. Part of this success is driven by our dedication to investing in our employees – and our Talent Acquisition team wants to continue to build and expand our…
-
Next Stop: Helping those with PKU
As the expression goes, “the journey is more important than the destination.” For Global Project Leader Neil Smith, PharmD, MBA, both are equally important, as improving the lives of other people is the ultimate destination. Smith has kept this end goal in mind throughout his journey working on PTC923 – an oral therapy in development…
-
PTC in 2021: A Year of Expansion
For PTC, 2021 was about expansion – not just literally, as we grew our global reach and added team members, but what we can do for patients, too, through our awareness efforts and continued dedication to scientific innovation. Expansion by definition is the act of becoming larger or more extensive. And in fact, we had so much good news in 2021, it was hard for us to pick the highlights to include…
-
Ever Better: Striving to Improve Clinical Trials for Patients
Recently, Clinical Leader published a guest column by PTC Chief Development Officer Matthew B. Klein, MD, MS, FACS. Dr. Klein brings many years of experience working directly with patients undergoing hospital treatments and clinical studies to his work at PTC. His honed perspective has led him to identify three ways our life sciences industry can…
-
Our Commitment to the Rare Disease Community
PTC was founded in 1998 by a scientist with a desire to serve patients with rare diseases and unmet medical needs. Over the course of our history, we have grown to a team of more than a thousand employees and developed new innovative therapies. However, we’ve always maintained our foundational commitment to our patients and…